Spironolactone and altizide in systemic hypertension: Ambulatory multicenter study

Sternon, J

doi:10.1016/0002-9149(90)91273-9

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mineralocorticoid receptor antagonists are effective in reducing blood pressure (BP) when used as monotherapy or in combination regimens . MRAs have been shown to be as effective as ACE inhibitors or ARBs in lowering BP .…”

Section: Mineralocorticoid Receptor Antagonists For Systemic Hypertenmentioning

confidence: 99%

Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure

Iqbal

Parviz

Pitt

et al. 2013

European J of Heart Fail

View full text Add to dashboard Cite

Clinical trials have demonstrated morbidity and mortality benefits of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. These studies have used either spironolactone or eplerenone as the MRA. It is generally believed that these two agents have the same effects, and the data from studies using one drug could be extrapolated for the other. National and international guidelines do not generally discriminate between spironolactone and eplerenone, but strongly recommend using an MRA for patients with heart failure due to LV systolic dysfunction and post-infarct LV systolic dysfunction. There are no major clinical trials directly comparing the efficacy of these two drugs. This article aims to compare the pharmacokinetics and pharmacodynamics of spironolactone and eplerenone, and to analyse the available data for their cardiovascular indications and adverse effects. We have also addressed the role of special circumstances including co-morbidities, concomitant drug therapy, cost, and licensing restrictions in choosing an appropriate MRA for a particular patient, thus combining an evidence-based approach with personalized medicine.

show abstract

Section: Mineralocorticoid Receptor Antagonists For Systemic Hypertenmentioning

confidence: 99%

Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure

Iqbal

Parviz

Pitt

et al. 2013

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…15,17 Only one hypertension trial included both spironolactone and eplerenone. This fixed-dose, placebocontrolled trial compared the safety, efficacy, and tolerability of eplerenone (50-400 mg/day) with placebo.…”

Section: Hypertensionmentioning

confidence: 99%

A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone

Struthers

Krum

Williams

2008

Clinical Cardiology

223

146

View full text Add to dashboard Cite

Improved understanding of the adverse pharmacological properties of aldosterone has prompted investigation of the clinical benefits of blocking aldosterone at the receptor level. This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and eplerenone. A Medline search identified clinical studies assessing spironolactone and eplerenone. Priority was given to large, wellcontrolled, clinical trials and comparative studies. Pharmacological differences between spironolactone and eplerenone include lower affinity of eplerenone for progesterone, androgen, and glucocorticoid receptors; more consistently demonstrated nongenomic properties for eplerenone; and the presence of long-acting metabolites for spironolactone. Both agents effectively treat hypertension and heart failure but comparisons are complicated by the deficiency of head-to-head trials and differences between patient populations. There are differences in the tolerability profiles; spironolactone is associated with dose-dependent sexual side effects. Both agents produce dose-dependent increases in potassium concentrations, although the effect with spironolactone appears to be greater when both agents are administered at recommended doses. Choice of a specific agent should be based on individual patient issues, such as the nature of heart failure and patient concerns about adverse events.

show abstract

Development of Polar Organic Mode Chromatographic Method by Polysaccharide-Based Immobilized Chiral Selector and Validation for the Determination of the Enantiopurity of Novel Mineralocorticoid Receptor Antagonist Atropisomer–Esaxerenone

et al. 2022

View full text Add to dashboard Cite

Spironolactone and altizide in systemic hypertension: Ambulatory multicenter study

Cited by 3 publications

References 4 publications

Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure

Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure

A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone

Development of Polar Organic Mode Chromatographic Method by Polysaccharide-Based Immobilized Chiral Selector and Validation for the Determination of the Enantiopurity of Novel Mineralocorticoid Receptor Antagonist Atropisomer–Esaxerenone

Contact Info

Product

Resources

About